The inhibition of slow-channel activity in vascular smooth muscle and myocardium produces a wide range of beneficial effects in various cardiocirculatory disorders, such as arrhythmias, myocardial ischemic syndromes and hypertension. As in the case of ,B antagonists, slow-channel inhibitors constitute a heterogeneous group with a variable degree of selectivity for heart muscle, atrioventricular conduction, peripheral vessels and the coronary circulation. Their hemodynamic effect is the net result of a complex interplay of simultaneous changes in heart rate, preload, afterload, contractility and coronary blood flow. In animals, these agents reduce myocardial ischemic injury and may enhance collateral perfusion; in man, they have salutary effects in exertional angina in which they probably act by reducing cardiac work, an effect quantitatively not dissimilar to that produced by : antagonists. This approach thus provides an alternative mode of medical therapy for patients with exertional angina who do not tolerate d blockers or in whom blockers are contraindicated by the presence of bronchospasm or peripheral vascular disease. However, the major additional advantage that slow-channel antagonists unquestionably have over blockers is the fact that they all are potent coronary vasodilators. In contrast, antagonists constrict coronary vessels. For this reason, the advent of slow-channel inhibitors such as verapamil, nifedipine and diltiazem is a very timely landmark in relation to the wealth of data that have confirmed the belief that coronary vasospasm plays an important role not only in the pathogenesis of classic variant angina, but also in many patients with unprovoked angina, myocardial infarction or sudden death in the setting of diseased as well as normal coronary arteries. For a patient who has normal or relatively normal coronary vessels but who develops vasospastic angina, slow-channel inhibitors are likely to become the agents of choice and preliminary clinical experience is in line with these considerations. Similarly, patients who have exertional and vasospastic angina are more likely to derive greater behefits from slow-channel inhibitors than from blockade, which may aggravate coronary spasm. Evidence also indicates that certain slow-channel antagonists may be useful in other cardiocirculatory disorders, such as acute pulmonary edema, acute hypertensive emergencies and obstructive cardiomyopathies. Such indications, if confirmed, will broaden the clinical usefulness of this class of compounds, whose introduction is likely to be a significant advance in cardiovascular therapeutics. IN THE PAST 2 decades major advances have taken place in the development of many classes of drugs for the control of myocardial ischemic syndromes, hypertension and cardiac arrhythmias.' Many of these exert beneficial effects in patients who have all three disorders. For example, fl antagonists relieve angina;
they reduce blood pressure and are effective in certain cardiac arrhythmias. 2 3 Similarly, benzfuran derivatives (amiodarone is a prototype) are powerful anti-arrhythmic4 5 and antianginal agents that also reduce arterial pressure by producing vasodilatation. Although data from sporadic reports confirm the unique properties of amiodarone reported 10 years ago,4 systematic studies aimed at its introduction into the United States are apparently not planned. This is in sharp contrast to the status of drugs known as slowchannel inhibitors or calcium antagonists.5 These are now under intensive clinical investigation. Their general release is likely to be a significant therapeutic advance in cardiology. The aim of this paper is to review briefly the physiologic and pharmacologic aspects of slow-channel blockade in heart and vascular smooth muscle relative to the overall clinical 669 i VOL 62 NO 4 1980 VOL 62, No 4, OCTOBER 1980 usefulness of slow-channel inhibitors in cardiocirculatory disorders.
Slow-channel Activity in Cardiac and Vascular Smooth Muscle Although the precise mechanism of excitationcontraction (EC) coupling in most contractile tissues is still uncertain, information is available from voltage clamp studies6' 7 that clarifies the ionic basis of depolarization in excitable membranes.
Voltage clamp has shown that in cardiac muscle the early depolarizing currents can be separated into a kinetically fast component (fast response) carried by Na+ and kinetically a slower component (slow response) carried mostly, but not exclusively, by Ca++. These two currents, which flow through separate channels, have very different electrophysiologic properties. The fast Na+ channel has rapid activation and inactivation kinetics; its threshold for activation is between -60 to -70 mV, with a correspondingly high resting potential (-80 to -95 mV). It also has a largeamplitude action potential with a rapid rate of rise and conduction velocity, ensuring a high safety factor for conduction. Muscle fibers dependent on the fast channel for activation respond to a stimulus in all-ornothing fashion and, under physiologic conditions, the recovery of their excitability is prompt with the completion of repolarization. Furthermore, the fast channel is selectively inhibited by tetrodotoxin (TTx), local anesthetics or low Na media, but is not influenced by catecholamines except indirectly in "depressed" tissues. Here, hyperpolarization of the membrane by sympathomimetic amines augments the fast response. While TTx and local anesthetics both depress the fast channel, the underlying mechanisms may differ.7 For example, TTx blocks the Na channel in an all-or-nothing fashion, but it does not alter its kinetics. In contrast, different local anesthetics inhibit the fast Na-channel activation while altering the kinetics of inactivation and reactivation to different degrees. With the exception of nodal tissues, most myocardial fibers are dependent on fast-channel activity for conduction. Thus, the early, rapid portion of the action potential upstroke is determined solely by the fast channel. In contrast, activation of the slow current determines to a large extent the last part of the action potential upstroke in most atrial, ventricular and Purkinje fibers; it is also responsible for EC coupling and the plateau phase of the action potential. The slow channel is particularly significant in the early upstroke of the action potential in the atrioventricular (AV) node.
Although the slow channel is often called a Ca++ channel, Ca++ and Na+ ions are charge carriers for this channel. However, the extent to which Ca++ and Na+ contribute to the slow current may differ not only among atrial, ventricular and Purkinje fibers, but also from one animal to another. In the case of the slow channel, the kinetics of activation and inactivation are slower than those of the fast channel and the threshold voltage for activation is much lower. The resting membrane potential, action potential amplitude and overshoot in fibers with slow-channel activity are also much smaller and, above all, the associated conduction velocity is about one-tenth that of the fastchannel-dependent fibers. Moreover, in slow-channeldependent fibers, the recovery of excitability is not coincident with the end of repolarization, i.e., the length of the effective refractory period outlasts the entire action potential duration. Since the threshold for the activation of this channel is about -30 to -40 mV, the slow response is particularly prone to arise in partially depolarized fibers as in ischemia. Here, slowchannel activity may give rise not only to reentrant excitation caused by excessively depressed conduction, but also to ectopic tachyarrhythmias caused by oscillatory phenomena, which are augmented by low Na+-high Ca++ media and catecholamines. An indirect characterization of the slow channel is possible because it is selectively inhibited by metals such as cobalt, lanthanum and manganese. An almost identical effect is produced by other compounds (verapamil, D600, nifedipine and diltiazem) in concentrations at which they do not influence the fast channel. This effect has formed the basis for categorizing such agents as slow-channel inhibitors.
Slow-channel inhibitors also block EC coupling in vascular smooth muscle; they may therefore produce variable degrees of coronary and peripheral vasodilatation.8 The precise ionic mechanisms underlying EC coupling in smooth muscle are still poorly understood,8 'o but it is known that contraction and relaxation in this tissue are determined largely by the distribution, transmembrane and intracellular movements of Ca++.9' 11 Recently, the concept9 has emerged that there are at least two Ca++-activation systems in mammalian smooth muscle. The first can be blocked selectively by the typical slow-channel inhibitor verapamil and is preferentially involved in producing phasic mechanical activity. The other mechanism, resistant to such slow-channel inhibitors, is preferentially involved in producing tonic mechanical activity and is suppressed by sodium nitroprusside.
Pharmacologic Considerations
Although inhibition of slow-channel activity in cardiac muscle is a feature common to many chemically heterogeneous compounds," only a few have therapeutically desirable features in common. Some are likely to become clinically available in this country. The most promising are verapamil, nifedipine and diltiazem ( fig. 1 ). While all of these drugs have the propensity to block the slow channel in isolated tissues, their net effect in vivo may vary considerably. The differences may relate to their associated properties, such as the ability to nonspecifically block sympathetic excitation. They may also show quantitative differences in their proclivity to inhibit EC coupling in cardiac tissues or vascular smooth muscle. Such variations undoubtedly account for differences in their net hemodynamic effects, their overall therapeutic properties and their adverse reactions. The similarities and differences in the cardiovascular responses of verapamil, nifedipine and diltiazem are listed in table 1. The salient features of their clinical pharmacology are presented in table 2. Reasonably detailed studies, including a number from the U.S.'2' 13 with verapamil and nifedipine, are available, while the data are increasing rapidly in the case of diltiazem.' In in vitro studies, verapamil was found to inhibit the slow channel in cardiac'7 18 and vascular smooth'9' 20 muscle in concentrations in which it has little effect on the fast channel, despite its welldocumented local anesthetic action on nerve." 21 The resting membrane voltage or the overall action potential duration were unaffected, with a slight acceleration of phase 3. Voltage clamp studies have shown that the levo-isomer of verapamil inhibits the kinetics of the slow current while delaying its activation, especially the time course of its recovery from inactivation.22' 23 Furthermore, in isolated tissues verapamil produced a significant negative inotropic effect while depressing the firing frequency of the sinoatrial (SA) node. The effect on the sinus frequency is in part due to its direct action on the slow-channel activity in nodal tissues and in part related to the drug's noncompetitive antisympathetic actions.24 In vivo, these changes are greatly modified by the drug's TAIBLE . D600 is a slow-channel antagonist, but it is more depressant on the myocardium and has no advantages over verapamil.
The effect of each drug is indicated by 0, +, ++. +++ or ++++, with 0 meaning no effect and ++++ being the most potent effect.
Abbreviation: EC = excitation-contraction. potent peripheral vasodilator properties. For example, the resulting hypotension reflexly increases contractility and heart rate so that no net change in heart rate usually occurs. The depressant effect on the SA node is largely offset by the reflex response. Similarly, the reduction in contractility due to interference with EC coupling is not translated into a corresponding reduction in cardiac output'2 25 because the associated afterload reduction outweighs the depressant effects of the drug in therapeutically relevant doses except in patients with ventricular dysfunction.25 There are significant differences between the pharmacologic properties of verapamil and nifedipine (table 1) that may account for the spectrum of their clinical effects. In particular, despite the fact that nifedipine depresses slow-channel activity in isolated cardiac muscle, it has minimal direct depressant effects on the sinus frequency or AV conduction. '3 22 The electrophysiologic mechanisms that underlie such dissimilar effects of verapamil and nifedipine on heart muscle are not clear, but may relate to the ways in which they affect the kinetics of the slow channel. For example, in voltage clamp studies nifedipine was found to reduce the slow inward current in a dosedependent manner without affecting the kinetic parameters of the current, i.e., the drug reduces the number of channels but does not alter the time course of the activation, inactivation or recovery from in activation of the slow channel. 23 In contrast, verapamil 671 VOL 62, No 4, OCTOBER 1980 (or at least its levo-isomer) has a marked influence on the rate of activation, inactivation and particularly of recovery after inactivation of the slow current. 23 However, whatever causes are established for the differences in the properties of verapamil and nifedipine, the clinical relevance of the fact that nifedipine does not depress SA or AV nodal functions is clear. It accounts for the fact that nifedipine (unlike verapamil) does not promptly terminate AV nodal reentrant paroxysmal supraventricular tachycardia (PSVT). Similarly, the lack of a direct depressant action on the SA node and the absence of antisympathetic effect result in reflex increases in heart rate and contractility in response to peripheral vasodilatation induced by nifedipine. In this respect, the overall cardiocirculatory effects of nifedipine closely resemble those of conventional vasodilators. The direct depressant effect of the compound caused by slow-channel inhibition in the heart is largely nullified by the drug's peripheral vasodilator properties.26 Such an effect appears less "complete" for verapamil: Its overall hemodynamic effects vary with the level of ventricular function. The myocardial depressant action of the drug may be completely offset in cases with normal or moderately reduced ventricular function,12 whereas it may be only partially or not at all offset in patients with severely compromised hemodynamics.
The pharmacologic properties of diltiazem have not yet been delineated in detail.14-16 However, the data suggest that the compound is more akin to verapamil than to nifedipine (table 1): It depresses SA and AV nodal functions,27 dilates coronary and peripheral vessels and noncompetitively antagonizes sympathetic excitation. 16 The data thus indicate that the expanding range of slow-channel inhibitors does constitute a therapeutically meaningful family of compounds despite their structural heterogeneity. Their clinical usefulness is the result of the fact that they all are potent peripheral and coronary vasodilators with individual differences in their proclivity to depress SA and AV nodal functions or myocardial contractility. Such a spectrum of action of these compounds is reflected in the correspondingly variable potency in those cardiocirculatory disorders in which slow-channel blockade may become a significant addition to existing therapy.
Therapeutic Applications The potential clinical applications of slow-channel inhibitors are listed in table 3. The indications for the three antagonists are not identical, as might be expected from their variable electrophysiologic and pharmacologic properties. Their net therapeutic effects must be anticipated and interpreted individually because they produce a complex interplay of simultaneous alterations in preload, afterload, contractility, heart rate, AV conduction and coronary blood flow.
Cardiac Arrhythmias
The most significant antiarrhythmic effects of slowchannel inhibitors are their direct electrophysiologic actions.5' 24 Experimental data indicate that the depression of the slow response by selective slowchannel inhibitors in pathologic tissues may abolish arrhythmias due to reentry as well as automaticity. These compounds may also ameliorate myocardial ischemia by relieving coronary vasospasm28or by influencing myocardial metabolism,24 so they may 672 CIRCULATION SLOW-CHANNEL BLOCKADE/Ellrodt et al. favorably influence arrhythmias indirectly. Nifedipine appears to have no direct antiarrhythmic effects;22 few data are available relative to the antiarrhythmic properties of diltiazem, although its known electrophysiologic effects on AV conduction27 suggest that its action may be similar to that of verapamil, which has been studied most in this regard.5
The clinical electrophysiologic studies with verapamil are in substantial agreement with the experimental data. For example, in patients in sinus rhythm, i.v.
verapamil had no effect on the RR, QRS and QTc intervals of the ECG,3" with predictable increases in the PR interval. During His bundle studies verapamil impeded AV conduction proximal to the His bundle without affecting intraatrial or intraventricular conduction. 32 35 The conduction delay was in the AV node and was largely independent of autonomic influences. 35 The effect of verapamil on AV conduction is of clinical significance because it is the fundamental mechanism by which the ventricular response in atrial fibrillation and flutter is controlled and AV nodal reentrant PSVT is abolished.3' However, programmed stimulation has revealed that the drug has minimal effect on antegrade or retrograde conduction or refractoriness of the accessory pathways in preexcitation. 36 It is thus unlikely to be of value in the treatment of this syndrome complicated by atrial flutter or fibrillation,3' and may even be deleterious.
In contrast to the experimental data, clinical experience with verapamil indicates a narrow antiarrhythmic spectrum.24 31 Indeed, i.v. verapamil (5-15 mg, average 10 mg) has been found to promptly terminate 90-100% of the paroxysms of PSVT, a success rate of reversion unmatched by any other drug. The efficacy of verapamil in this context does not depend on whether reciprocation occurs within the AV node or whether it involves an anomalous tract, provided the ventricular activation occurs through the impulse traversing the AV node antegradely. The mode of conversion is variable and has been discussed elsewhere.24 While the role of i.v. verapamil in terminating acute PSVT is no longer in doubt, the efficacy of the orally administered drug in preventing recurrences of PSVT, when used alone or in combination with other agents, is not known. Published reports on these subjects are scanty and do not resolve the question of whether the drug is of prophylactic value for PSVT.
The inhibitory effects of i.v. verapamil on AV conduction have also been used to control the ventricular response in atrial fibrillation and flutter.5' 24 However, the effect is short-lived and ill-sustained unless a continuous infusion is used. The clinical value of orally administered verapamil in controlling ventricular response in atrial flutter and fibrillation was recently Few data indicate that calcium antagonists are effective in treating ventricular arrhythmias'4' 31 except in instances in which such dysrhythmias arise in the wake of coronary vasospasm with transmural myocardial ischemia. The role of the slow response in the genesis of ischemic ventricular arrhythmias is somewhat controversial,40 but slow-channel inhibitors may improve electrical conduction in ischemic myocardium,41 an action that may produce salutary effects on dysrhythmias after coronary occlusion. Therefore, the effects of these agents on ischemic myocardial syndromes are of greater therapeutic significance than their primary role in the control of ventricular dysrhythmias.
Myocardial Ischemic Syndromes
The overall cardiovascular properties of slowchannel inhibitors lend themselves well for studies with regard to their potential applications in virtually all myocardial ischemic syndromes due to reversible or fixed coronary arterial stenosis. Although still tentative, data suggest an important role for slowchannel inhibitors in the preservation of ischemic myocardium and in the management of stable and unstable angina,4247 particularly in cases in which coronary vasospasm4' 15, 30-32 is a major factor in the pathogenesis of ischemia.
Preservation of Ischemic Myocardium
Many reports have shown that the course of acute myocardial ischemia after coronary occlusion may be influenced by pharmacologic and metabolic interventions.48' 49 However, we do not know whether such salutary effects result in lower morbidity and mortality from acute myocardial infarction if the intervention is applied in the early phases of coronary occlusion in man. Numerous regimes are being evaluated clinically relative to this possibility, but slow-channel inhibitors are of particular significance in this context. First, the transmembrane Ca++ influx may be the major cause of structural damage that accompanies coronary reperfusion,"0 and slow-channel inhibitors might be expected to reverse the ischemic trend. Second, because slow-channel inhibitors reduce myocar-dial ATP consumption and inhibit EC coupling," they reduce myocardial oxygen requirements, an effect accentuated by the afterload-reducing actions of the drugs. Finally, slow-channel inhibitors are potent coronary vasodilators, so they may enhance collateral blood flow,'3 thereby ensuring tissue viability after coronary occlusion.
The role of verapamil in minimizing the severity of ischemic injury was first suggested by Sodi-Pallares et al. ' 1 They reported that the drug either prevented or reversed the ECG manifestations of myocardial ischemia in the dog. Even more significant was the report by Kaumann and Aramendia,52 who found that dogs pretreated with i.v. verapamil before coronary occlusion failed to develop ventricular fibrillation and survived for many months, whereas animals similarly treated with / blockade always died from ventricular fibrillation within 24 hours of coronary occlusion. These results suggested that verapamil might act by containing the extent of the initial ischemic injury, thereby contributing to fewer arrhythmias and to improved survival rate. Subsequent studies showed that the drug improves hemodynamics in experimental infarction,53 with beneficial effects on the extent of tissue necrosis in the dog.." Pretreatment with verapamil before coronary ligation in anesthetized animals resulted in significantly less necrosis (14% treated vs 35% untreated), with minimal hemodynamic consequences. In another study55 in the isolated perfused heart, verapamil reduced the extent of ultrastructural damage caused by hypoxic perfusion. Protective effects on the ischemic myocardium have also been reported recently for diltiazem5' and nifedipine.13 57 Henry et al.'3 showed that when nifedipine was infused continuously after coronary occlusion in conscious dogs, collateral blood flow was augmented in the ischemic zones and less depletion of myocardial CK activity occurred, consistent with "salvage" of ischemic tissue. Tentative data also indicate that slowchannel inhibitors may be of value intraoperatively in preserving myocardium during myocardial revascularization for coronary artery disease. 22 However, while the concept of salvaging ischemic myocardium during cardiac surgery or in the early stages of acute myocardial infarction by pharmacologic means is attractive, its therapeutic role is far from clear. Stringently controlled clinical trials are needed to evaluate the short-term and long-term benefits of such drug interventions as Ca++ antagonists designed to preserve ischemic myocardium.
Chronic Stable Angina
The prophylactic use of slow-channel inhibitors in angina pectoris was suggested by their potent coronary vasodilator property. However, this is probably not the basis for their action in relieving exertional angina. Indeed, while many reports purport to establish the efficacy of verapamil and nifedipine in reducing the frequency of angina in patients with chronic stable symptoms, conclusive studies using objective end points are few.
The earliest study was that of Neumann and 674 CIRCULATION SLOW-CHANNEL BLOCKADE/Ellrodt et al.
Luisada.'2 In their double-blind trial the effects of oral verapamil, 40 mg three times daily, vs placebo on the weekly consumption of nitroglycerin in 30 geriatric patients with stable angina were evaluated. Significantly fewer nitroglycerin tablets were used during the 6-week period on verapamil compared with that on placebo. There were no objective end points in this study, and small doses of verapamil were used, so no conclusions could be drawn regarding the efficacy of the drug. More objective parameters were used by Sandler et al.,43 who found in a controlled study in 16 patients with stable exertional angina that the effects of 120 mg of verapamil three times daily were comparable to those of 100 mg three times daily of propranolol in terms of a significant decrease in the frequency of angina and improvement in exercise tolerance. In these doses, both drugs had a beneficial effect on the amount and duration of ischemic STsegment depression during exercise. The lower dose of verapamil (40 mg three times daily), however, had no effect. Unlike propranolol, verapamil had no effect on the resting or exercise heart rate, and systolic blood pressure was also unchanged, so we may infer that myocardial oxygen was also unaltered. Thus, the mechanism of the antianginal action of verapamil in this study was unclear.
In a very similar double-blind study comparing verapamil, propranolol and isosorbide dinitrate in 32 patients with stable angina, Livesley et al.4 found no statistically significant difference between the effects of verapamil, 120 mg three times daily, and propranolol, 100 mg three times daily. Both regimens were more effective than a placebo in reducing daily attacks of angina and in prolonging exercise tests. Both verapamil and propranolol reduced diastolic blood pressure and resting heart rate and exercise tachycardia. The conflicting reports of Sandler et al. 43 and those of Livesley et al.4 on the effects of verapamil on resting heart rate and exercise tachycardia are not readily explained. Study populations may have been different, possibly with variable drug absorption characteristics. Subsequent studies45' 46 have supported a significant antianginal efficacy for verapamil in stable angina. In the Multicenter Danish Study, the effect of 80 mg of verapamil three times daily on angina pectoris compared with a placebo was studied in a double-blind cross-over trial of two 4week periods in 47 patients with stable exertional angina. The frequency of anginal attacks and nitroglycerin consumption was 25% lower during verapamil therapy, with significant improvement in exercise tolerance as judged by bicycle ergometry. However, the exercise-induced tachycardia was not reduced by verapamil, although the average resting heart rate on verapamil was lower than that on the placebo.
In the study of Balasubramanian et al.,'6 the efficacy of verapamil in a dose of 120 mg three times daily was evaluated in 25 patients with stable chronic angina. The patients were subjected to serial measured multistage treadmill exercise without any drugs and after 40 mg of propranolol three times daily for three days; the tests were then repeated after 2, 4, and 8
weeks of verapamil therapy. The evaluation was based on computerized ST-segment alterations, anginal threshold and ECG changes. Anginal threshold was increased by verapamil in all patients, and eight of the 13 symptomatic patients became pain-free and showed significant improvement in the ischemic ECG patterns in all cases. The resting and exercise heart rates were reduced by verapamil, but not to the same extent as by propranolol. No patient developed AV block, significant hypotension or heart failure during the trial and side effects from verapamil were limited to transient constipation in four patients. These results on the antianginal effects of verapamil43-46 are thus encouraging, but the limitations of the published reports in terms of small numbers of patients and often, lessthan-objective parameters of efficacy need to be emphasized. Atrial pacing studies with the measurements of transmyocardial gradients of lactate and oxygen before and after drug infusion or after chronic therapy will clearly be of much interest.
The antianginal effects of diltiazem have not been investigated extensively except in patients with vasospastic angina; in contrast, many reports58-61 have suggested that orally or sublingually administered nifedipine delays the onset of ischemic pain induced by treadmill stress, increases the duration of exercise and minimizes the accompanying ischemic changes on the ECG. However, in almost all such studies, few patients have been evaluated and the placebo control phase has been inadequate. The data are suggestive rather than conclusive for efficacy of nifedipine in exertional angina. Nifedipine has been used in 10-20-mg doses three times daily. In such doses, side effects are uncommon but headaches, flushing, dizziness and nausea may develop. Unlike verapamil, nifedipine may induce reflex increases in heart rate and contractility in response to abrupt decreases in arterial pressure, which may aggravate myocardial ischemic pain in some patients.62 It is likely that such an effect may be prevented by the concomitant administration by sympathetic blocking agents. It will be important to compare the antianginal efficacy of nifedipine to that of other slow-channel inhibitors and d antagonists using adequate numbers of patients and stringently designed protocols that use objective end points as test variables. Only data from such comparative studies will permit delineation of the ultimate role of nifedipine and other slow-channel inhibitors in the management of chronic stable angina.
While the initial data suggest that slow-channel inhibitors such as verapamil and nifedipine are effective in chronic stable exertional angina, their mechanism of action is uncertain. Nifedipine is an extremely potent peripheral vasodilator,60 and its hemodynamic actions suggest that it may produce its salutary effects in angina by reducing cardiac work because of the change in afterload. It must be emphasized, however, that at least in part, the reduction in myocardial oxygen consumption (MVO2) effected by nifedipine through this mechanism must be offset by reflex increases in heart rate and contractility secondary to peripheral vasodilatation. Such reflex effects are less pronounced in the case of verapamil and diltiazem, 675 VOL 62, No 4, OCTOBER 1980 both of which are noncompetitive sympathetic inhibitors. '3' 16 While the in vitro data clearly indicate that these agents reduce MVO2, results from clinical studies are more variable.63 For instance, verapamil does not reduce the gross indexes of MVO2 as judged by changes in heart rate times blood pressure product at rest.63 However, it increased coronary sinus flow resulting from the dilatation of both resistance as well as conductance coronary vessels.6" Particularly noteworthy has been our observation with computerassisted angiographic analysis that coronary caliber was significantly increased in normal, minimally and severely diseased arterial segments in patients with coronary artery disease who were studied at cardiac catheterization.6' These data do not suggest that coronary dilatation plays a role in mediating the beneficial effect of verapamil in chronic stable angina. However, the demonstration that agents such as verapamil can dilate diseased and normal coronary vessels form the rational basis for the therapeutic usefulness of slow-channel inhibitors in vasospastic angina. This indication is likely to assume major importance in the management of this clinical entity, which is increasingly recognized in the spectrum of coronary artery disease. 65 66 Vasospastic Angina The development and characterization of slowchannel inhibitors as potent coronary vasodilators in the last 10 years is timely. Many investigations have vindicated the possibility that clinical ischemic syndromes may result not only from increases in MVO2 in patients with fixed coronary reserve, but also from primary decreases in blood flow due to abnormal alterations in the reactivity of normal or atherosclerotic coronary vessels.65-67 For example, although the trigger mechanism is still uncertain in most instances, there is little doubt that coronary vasoconstriction (spasm) is indeed the fundamental cause of ischemia in variant angina.67' 68 The documentation of this action has had significant therapeutic implications. Verapamil,28 nifedipine29 10 and diltiazem", 15 have all been shown to be strikingly effective in controlling frequent attacks of variant angina resistant to / blockers with or without nitrates. Repeated attacks of ventricular fibrillation complicating attacks of variant angina have also been shown to respond to slow-channel inhibitors.69' 70 The antiarrhythmic mechanism here is likely to be secondary to the amelioration of myocardial ischemia resulting from coronary vasospasm. Yasue et al. 15 showed that recurrent episodes of variant angina in patients subject to coronary vasospasm were aggravated by /adrenergic blockade but were abolished by orally administered diltiazem. However, none of the reports on the effects of slow-channel inhibitors in variant angina are based on adequately controlled studies. Thus, stringently designed clinical trials are needed to define the role of slow-channel inhibitors in the prophylaxis of variant angina, even though a rational basis for their use in this setting exists.
Recent work has also indicated that the therapeutic usefulness of slow-channel inhibitors in the control of myocardial ischemia may not be confined to their use in variant angina. Continuous hemodynamic and ECG monitoring in patients with ischemic chest pain at rest has shown that increases in pulmonary capillary wedge pressure and ECG abnormalities may develop for varying periods in many patients not only before the onset of chest pain, but also before increases in heart rate and blood pressure,65' 71 the main determinants of MVO2. In patients in whom coronary angiography and radionuclide myocardial perfusion studies could be done during spontaneous episodes of angina, there was clear evidence for a primary reduction in myocardial flow as a mechanism for ischemia in many patients with coronary artery disease who had angina at rest.65 Indeed, careful observations in Pisa and elsewhere65' 66, 71, 72 have suggested a continuous spectrum of vasospasm as causing unstable angina, myocardial infarction and sudden death in patients with fixed coronary artery lesions and in those without. The proportion of such patients in whom the initiating factor for the ischemic event is essentially vasospasm is, of course, not known, but is clinically significant with respect to the choice of a therapeutic agent. It is therefore of particular interest that in a double-blind cross-over study in the coronary care unit in 12 patients with unstable angina, verapamil appeared to be effective.47 After a 48-hour run-in period, verapamil 480 mg daily and placebo were given alternatively during four randomized 48-hour periods. Transient ischemic attacks with ST-segment elevation or depression were documented by continuous ECG recording. The number of attacks during the drug phases was significantly reduced (p < 0.003) compared with the number during the placebo therapy. This pilot study in 12 patients does not in itself establish the role of slow-channel inhibitors in unstable angina; it does, however, indicate that the efficacy of these agents should be compared to that of conventional regimes, particularly when coronary vasospasm may play a significant role in the development of ischemic syndromes. The current evidence favors the use of / antagonists in patients subject exclusively to exertional angina. In those in whom exertional angina and vasospastic angina coexist, slowchannel inhibitors appears preferable to / antagonists as prophylactic agents, but again, well-controlled trials are needed to provide the decisive answers. Slow-channel inhibitors would, however, appear to be the drugs of choice in patients whose ischemic syndromes arise primarily as a result of coronary vasospasm. In clinical situations in which /3 antagonists and slow-channel inhibitors are equally effective, slow-channel inhibitors will clearly have advantages over /3 blockers in patients who also have bronchospastic disorders.39
Other Potential Applications of Slow-channel Inhibitors The spectrum of clinical usefulness of slow-channel inhibitors must be evaluated ( However, neither nifedipine nor verapamil appears effective in the chronic treatment of hypertension. Nevertheless, nifedipine in particular may be useful for the chronic treatment of mild hypertension associated with angina pectoris or left ventricular failure. Of all the slow-channel inhibitors evaluated, nifedipine has the greatest propensity to produce peripheral vasodilatation, and in unanesthetized man it acts essentially as an impedance-reducing agent. It does not depress contractility of the normal or failing heart in vivo, suggesting that its negative inotropic effects are largely nullified by the unloading of the left ventricle and/or reflex sympathetic discharge. Alternatively, the minimal depressant effects of nifedipine may be related to the fact that the dose level producing substantial vasodilatation is less than that required to depress cardiac muscle. Whatever the mechanism, the initial experience of Polese et al. 26 indicates that the drug can be used as an effective ventricular unloading agent in acute pulmonary edema. In single (10-mg) sublingual doses, nifedipine has beneficial hemodynamic effects in acute congestive heart failure by effecting sustained falls in both preload and afterload and possibly by reflexly enhancing contractility. Compared with nitrates, nifedipine has a greater tendency to augment cardiac output, as it does not appear to induce significant venous pooling. 22 However, these data on the effects of slow-channel inhibitors in acute cardiac failure are preliminary; their role needs further critical evaluation.
Another potentially significant therapeutic application of slow-channel inhibitors is in the management of IHSS. Neither medical nor surgical therapy, both used in IHSS, are uniformly successful in this condition, and new approaches to therapy are of particular significance. Goodwin and Krikler75 suggested that arrhythmias arising on the basis of slow-channel activity may cause sudden death in IHSS. Moreover, reduction in contractility, as results from fi antagonists, does attenuate left ventricular outflow gradient and relieve obstructive symptoms. It is therefore interesting that Rosing et al.76' 7 reported on the hemodynamic effects of i.v. verapamil in 27 patients with IHSS. The drug reduced the basal left ventricular outflow tract gradient from 94 ± 14 to 49 ± 14 mm Hg (p < 0.001), with minor increases in cardiac index. Rosing et al. also demonstrated sustained improvement in exercise tolerance during chronic therapy. Thus, these preliminary data suggest a new approach in the control of the hemodynamic and arrhythmic consequences of obstructive cardiomyopathy, a mode of therapy alternative to ,B-adrenergic blockade that merits serious evaluation.
